n-methylaspartate has been researched along with Parkinson Disease, Secondary in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gray, TS; Mickiewicz, AL; Napier, TC; Turner, MS | 1 |
| Allbutt, HN; Coster, MJ; Henderson, JM; Kassiou, M; Truong, L | 1 |
| Achaval, M; Anselmo-Franci, JA; Delattre, AM; Ferraz, AC; Matheussi, F; Meneses, M; Rigon, P; Rizelio, V; Saur, L; Szawka, RE; Xavier, LL | 1 |
| Arjunan, P; Becker, KG; Cao, Y; Ding, H; Dong, L; Fariss, RN; Hou, X; Kumar, A; Lee, C; Lennartsson, J; Li, X; Li, Y; Nagai, N; Tang, Z; Wang, B; Wardega, P; Zhang, F; Zhang, SZ; Zhang, Y | 1 |
| Kanthasamy, A; Kanthasamy, AG; Matsumoto, RR; Truong, DD; Vu, TQ | 1 |
| Beani, L; Bianchi, C; Fuxe, K; Marti, M; Morari, M; Sbrenna, S | 1 |
| Brotchie, JM; Nash, JE | 1 |
| Boyce, S; Crossman, AR; Luquin, MR; Peggs, D; Sambrook, MA | 1 |
8 other study(ies) available for n-methylaspartate and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Fos expression following activation of the ventral pallidum in normal rats and in a model of Parkinson's Disease: implications for limbic system and basal ganglia interactions.
Topics: Animals; Basal Ganglia; Bicuculline; Brain; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Agonists; GABA Antagonists; Globus Pallidus; Immunohistochemistry; Limbic System; Male; Microinjections; N-Methylaspartate; Neurons; Oncogene Proteins v-fos; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Sympatholytics | 2008 |
Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA+parafascicular lesions.
Topics: Administration, Oral; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Excitatory Amino Acid Antagonists; Female; Immunohistochemistry; Intralaminar Thalamic Nuclei; Levodopa; Medial Forebrain Bundle; N-Methylaspartate; Neurons; Oxidopamine; Parkinson Disease, Secondary; Postural Balance; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Rotation; Tyrosine 3-Monooxygenase | 2009 |
Lesion of the subthalamic nucleus reverses motor deficits but not death of nigrostriatal dopaminergic neurons in a rat 6-hydroxydopamine-lesion model of Parkinson's disease.
Topics: Animals; Dopamine; Immunohistochemistry; Male; Motor Activity; N-Methylaspartate; Neurons; Parkinson Disease, Secondary; Pharmaceutical Vehicles; Random Allocation; Rats; Rats, Wistar; Substantia Nigra; Subthalamic Nucleus; Tyrosine 3-Monooxygenase | 2010 |
Survival effect of PDGF-CC rescues neurons from apoptosis in both brain and retina by regulating GSK3beta phosphorylation.
Topics: Animals; Antibodies; Apoptosis; Apoptosis Regulatory Proteins; Brain; Brain Ischemia; Capillary Permeability; Cell Survival; Cerebral Cortex; Female; Gene Expression; Gene Expression Profiling; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hydrogen Peroxide; Lymphokines; Mice; Mice, Inbred C57BL; Mice, Knockout; N-Methylaspartate; Neovascularization, Pathologic; Nerve Growth Factors; Neurons; Optic Nerve Injuries; Parkinson Disease, Secondary; Phosphorylation; Platelet-Derived Growth Factor; Rats; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Retina; Retinal Ganglion Cells; Retinal Vessels; Stroke Volume; Substantia Nigra; Tyrosine 3-Monooxygenase | 2010 |
Neuroprotective effects of the strychnine-insensitive glycine site NMDA antagonist (R)-HA-966 in an experimental model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Dopamine; Dopamine Agents; Drug Resistance; Excitatory Amino Acid Agonists; Glycine Agents; Male; Mice; Mice, Inbred C57BL; N-Methylaspartate; Neurons; Neuroprotective Agents; Parkinson Disease, Secondary; Pyrrolidinones; Stereoisomerism; Strychnine | 1997 |
In vitro evidence for increased facilitation of striatal acetylcholine release via pre- and postsynaptic NMDA receptors in hemiparkinsonian rats.
Topics: Acetylcholine; Animals; Corpus Striatum; Dose-Response Relationship, Drug; Excitatory Amino Acid Agonists; Male; N-Methylaspartate; Nerve Degeneration; Organ Culture Techniques; Oxidopamine; Parkinson Disease, Secondary; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Sympatholytics; Synaptosomes | 1999 |
A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Corpus Striatum; Cyclic AMP; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; In Vitro Techniques; Male; N-Methylaspartate; Neuroprotective Agents; Oxidopamine; Parkinson Disease, Secondary; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptors, N-Methyl-D-Aspartate; Receptors, Purinergic P1; Signal Transduction | 2000 |
Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey.
Topics: Animals; Aspartic Acid; Dibenzocycloheptenes; Dizocilpine Maleate; Injections, Intramuscular; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; N-Methylaspartate; Parkinson Disease, Secondary | 1989 |